# Aktis Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aktis-oncology

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aktisoncology.com
- Total disclosed funding: $331M
- Latest round: Series B (Sep 20, 2024)
- Investors on record: 20

## About

Aktis Oncology, Inc. is a biotechnology company specializing in the development of precision radiopharmaceuticals focused on delivering targeted cancer therapies, primarily addressing significant unmet medical needs in oncology.Aktis Oncology, Inc., founded in 2021, is based in Boston, US. The company specializes in precision radiopharmaceuticals designed to target cancer cells specifically. The firm has engaged in three funding deals, with the most recent being a Series B round of USD 175.00 mn on September 20, 2024, co-led by Janus Henderson Investors, RA Capital Management, and RTW Investments, among others. The total amount raised by the company currently stands at USD 175.00 mn, which also reflects its latest funding round. The CEO of the company is Matthew Roden.Aktis Oncology specializes in the development of precision radiopharmaceuticals that leverage advanced platform technologies to deliver targeted therapies. Key offerings include alpha-emitting particles aimed at precisely targeting cancer cells, enhancing treatment options for patients with prevalent cancers. The company's innovative approach addresses unmet medical needs, particularly in tumors with limited treatment alternatives, and is intended for use by oncologists and healthcare providers across North America and Europe.Aktis Oncology generates revenue through collaborations with healthcare institutions and oncology clinics that utilize its precision radiopharmaceuticals. The company engages in direct sales agreements with hospitals and cancer treatment centers, which include ongoing support and training for medical staff. Pricing strategies are in line with market standards for advanced cancer therapies, reflecting the precision and effectiveness of their flagship products.In September 2024, Aktis Oncology, Inc. raised USD 175.00 mn in Series B funding to support the research and development of its radiopharmaceuticals. The company plans to design and launch new products to enhance its therapeutic offerings, targeting an expansion into additional markets in North America and Europe. The recent funding will facilitate these initiatives, enabling Aktis Oncology to broaden its footprint within the oncology sector and improve treatment options for cancer patients.

## Funding rounds

- Series B, Sep 20, 2024, $175M — T Rowe Price, Pappas Capital, Bristol-Myers Squibb Company, Eli Lilly & Company, RTW Investments, RA Capital Management, Janus Henderson Investors, MRL Ventures Fund, Avidity Partners Management Lp
- Series A, Aug 25, 2022, $84M — Pappas Capital, MPM BioImpact, Merck Global Health Innovation Fund, Bristol-Myers Squibb Company, ArrowMark Partners, EcoR1 Capital, Cowen Investment Management, Mirae Asset Venture Investment, Novartis, Timefolio Capital, Vida Ventures, Octagon Capital Advisors, TCG Crossover Management
- Series A, Mar 18, 2021, $72M — MPM BioImpact, Bristol-Myers Squibb Company, EcoR1 Capital, Novartis, Vida Ventures, Octagon Capital Advisors, TCG Crossover Management

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Bristol-Myers Squibb Company — Series A, Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- Novartis — Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series A
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A
- ArrowMark Partners — Series A
- Cowen Investment Management — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A
- Timefolio Capital — Series A
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Eli Lilly & Company — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Janus Henderson Investors — Series B
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series B
- Avidity Partners Management Lp — Series B